Efficacy and safety of AXS-07 in acute migraine
Key messages
- Over 70% of patients are not fully satisfied with their current treatments, mainly due to suboptimal efficacy, and 80% would try a new therapy.
- Ineffective acute treatment may contribute to medication overuse, chronification of migraine and poor long-term outcomes.
- AXS-07 treatment resulted in rapid, sustained, substantial and statistically significant efficacy compared to rizatriptan, meloxicam and placebo.
- AXS-07 provided significant benefit to patients with acute migraine and a history of inadequate response to prior treatments, even in patients with difficult-to-treat migraines.